Tag Archives: congress

House Ag Subcommittee Considers the Societal Benefits of Biotechnology

wheat

“Organic farmers do not need to demonize conventional farmers, we are one agriculture,” opened Ranking Member. Kurt Schrader (OR-05). On July 9, 2014 at 10:00am, the House Committee on Agriculture, Subcommittee on Horticulture, Research, Biotechnology, and Foreign Agriculture held a public hearing “To consider the societal benefits of biotechnology”. Witnesses included: Dr. David Just, Professor, Co-Director, Cornell Center for Behavioral Economics in Child Nutrition Programs, Charles H. Dyson School of Applied Economics and Management, Cornell University, Ithaca, Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

IPAB: Bad Medicine for Patient Care

DC in Fall

The Independent Payment Advisory Board is bad medicine for patient care, deficit reduction and containing Medicare costs. This board, consisting of 15 bureaucrats appointed by the President, has been given the power to make decisions affecting patients’ quality of care, with almost no oversight and no means for challenging its decisions. IPAB must be repealed. There is widespread support among patient advocacy groups and members of Congress on both sides of the aisle for full Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The Pivotal Role the Public Market Plays in Financing R&D

KennethMoch-Chimerix

Growing innovators are the heart of our industry. Biotech small businesses face a dual struggle – the daily challenge of running a growing company combined with the roadblocks intrinsic to groundbreaking scientific advancement. Innovative companies must overcome capital formation barriers in order to fund their next generation R&D.  The financing challenges that emerging biotechs face are unique, but we have the potential to save lives and treat patients in desperate need of hope. Today, I Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Nationwide Track and Trace System is Urgently Needed

Jim Greenwood

Today’s pharmaceutical distribution supply chain is governed largely by a patchwork of state laws and regulations that allows criminals to enter markets with the lowest safety requirements to inject counterfeit, unsafe, and potentially lethal products into the national supply chain. The state-by-state system is both onerous and ineffective, and the risk it poses to public health from counterfeiters can no longer be ignored. In a recent opinion piece for Roll Call, I write that: “Congress Read More >

Jim's Corner  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Sen. Grassley Raises Concerns over 340B Program

95468934

In a memo written this week, Sen. Chuck Grassley (R-IA) responded to a recent Kaiser Health News report by asking whether 340B-eligible hospitals are ‘doing everything possible to help uninsured patients receive health care, including affordable prescription drugs.’ 340B is an important safety net program designed to help uninsured indigent patients gain greater access to prescription medicines.  While there remains a need for this safety net program, there are emerging concerns about the program in Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,